[Progress in the pharmacotherapy of peptic ulcer].
D000468:Alkalies / Q000627:therapeutic use; D000535:Aluminum / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D004341:Drug Evaluation; D004815:Epidermal Growth Factor / Q000627:therapeutic use; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D009853:Omeprazole; D009942:Organometallic Compounds; D010437:Peptic Ulcer / Q000188:drug therapy*; D011377:Proglumide / Q000627:therapeutic use; D011459:Prostaglandins E, Synthetic / Q000627:therapeutic use; D013392:Sucralfate
D000468:Alkalies; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D006635:Histamine H2 Antagonists; D009942:Organometallic Compounds; D011459:Prostaglandins E, Synthetic; D013392:Sucralfate; D004815:Epidermal Growth Factor; D000535:Aluminum; D011377:Proglumide; C002791:bismuth tripotassium dicitrate; D009853:Omeprazole; D001729:Bismuth
Postepy w farmakoterapii choroby wrzodowej.